Abstract

Maintenance of bone quality is an ongoing challenge throughout the lifespan of a cancer survivor. Although bone metastases are the most obvious scenario in which a malignancy negatively affects bone, non-metastatic cancer can also impair bone metabolism by direct (eg, cancer mediated) or indirect (eg, treatment or consequences of such) mechanisms.1 Updated American Society of Clinical Oncology (ASCO) clinical practice guidelines were published in 2019 to provide guidance on how to monitor and treat adult patients with cancer and concurrent osteoporosis.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call